



Programs & Services Committee Budget Agenda

City of Newton In City Council

Wednesday, May 4, 2022

The Programs & Services Committee will hold this meeting as a virtual meeting on Wednesday, May 4, 2022 at 7:00 pm. To view this meeting using Zoom use this link: <https://us02web.zoom.us/j/89840176326> or call 1-646-558-8656 and use the following Meeting ID: 898 4017 6326.

Items scheduled for discussion:

#262-22 Appointment of Jin Zhang to the Biosafety Committee

PRESIDENT ALBRIGHT appointing Jin Zhang, 274 Auburndale Avenue, Auburndale, to the Biosafety Committee for a term of office to expire on May 16, 2025. (60 Days: 06/18/2022)

Referred to Programs & Services and Finance Committees

#244-22 Resolution on the Fair Share Amendment

COUNCILORS ALBRIGHT, RYAN, DOWNS, DANBERG AND LIPOF a resolution asking the City Council to support the Fair Share Amendment which will be on the November Ballot.

Please Note: Budget materials can be found on the City's website at the following link:

<https://www.newtonma.gov/government/comptroller/budget>

DEPARTMENT BUDGET & CIP DISCUSSIONS:

City Solicitor

Senior Services

Health & Human Services

Information Technology

Referred to Finance and Appropriate Committees

#213-22 Submittal of the FY23 to FY27 Capital Improvement Plan

HER HONOR THE MAYOR submitting the Fiscal Years 2023 to 2027 Capital Improvement Plan pursuant to section 5-3 of the Newton City Charter.

The location of this meeting is accessible and reasonable accommodations will be provided to persons with disabilities who require assistance. If you need a reasonable accommodation, please contact the city of Newton's ADA Coordinator, Jini Fairley, at least two business days in advance of the meeting: fairley@newtonma.gov or (617) 796-1253. The city's TTY/TDD direct line is: 617-796-1089. For the Telecommunications Relay Service (TRS), please dial 711.

Referred to Finance and Appropriate Committees

#213-22(2) Submittal of the FY23 Municipal/School Operating Budget

HER HONOR THE MAYOR submitting in accordance with Section 5-1 of the City of Newton Charter the FY23 Municipal/School Operating Budget, passage of which shall be concurrent with the FY23-FY27 Capital Improvement Program (#213-22).

EFFECTIVE DATE OF SUBMISSION 04/19/22; LAST DATE TO PASS THE BUDGET 06/03/22

Referred to Finance and Appropriate Committees

#213-22(3) Submittal of the FY23 – FY27 Supplemental Capital Improvement Plan

HER HONOR THE MAYOR submitting the FY23 – FY27 Supplemental Capital Improvement Plan.

Respectfully submitted,

Josh Krintzman, Chair

Nathan Giacalone

From: Susan Albright
Sent: Wednesday, April 6, 2022 9:45 AM
To: Nathan Giacalone
Cc: Amalia Timbers
Subject: docket item for Biosafety Committee
Attachments: Application-Jin Zhang.pdf

[DO NOT OPEN links/attachments unless you are sure the content is safe.]

Hi Nathan,
Would you docket this for me?

President Albright appointing Jin Zhang as a member of the Biosafety Committee

Include whatever else needs to be in the docket item. Attached is his resume - would you block out whatever is usually blocked out when you send a resume to the packet? I talked to him this morning and he is prepared to receive a phone call from you at some point asking about his availability to come to a meeting.

Thanks
Susan

Please find the contact information for Jin Zhang below...

[REDACTED]

[REDACTED]

[REDACTED]

--
Susan Albright, President
Newton City Council
Councilor-at-Large Ward 2

Application Form

Profile

Jin _____ Zhang _____
 First Name Middle Initial Last Name

 Email Address

274 AUBURNDALE AVENUE _____
 Home Address Suite or Apt

AUBURNDALE _____ MA _____ 02466 _____
 City State Postal Code

What Ward do you live in?

Ward 4

 Primary Phone Alternate Phone

GSK _____ Sr. Manager _____
 Employer Job Title

Which Boards would you like to apply for?

Biosafety Committee: Submitted

Interests & Experiences

Please tell us about yourself and why you want to serve.

Why are you interested in serving on a board or commission?

I always had interest in government and this board would allow me to combine that interest with my career background to serve the public. I'm also interested because of the proposed development at Riverside that will include biotech labs and my home's proximity to that development.

 Upload a Resume

SUMMARY

Seasoned bench scientist and people manager with extensive biologic and gene therapy cell line development experience from the Research to CMC, including Module 3 BLA preparation, cell banking & testing, and LIVCA. Additional upstream process development experience such as Ambr15, process characterization, small scale bioreactor model, process tech transfer, deviation/CAPA handling, and risk assessment. Experienced with CDMO and external research partner collaboration including project coordination, meeting management, SOW preparation, and procure to pay. Hands-on experience with Operational Excellence/Lean methodologies, workshops, projects, and implementations. Trained in Sanofi Manufacturing System (Six Sigma Green Belt equivalent).

COMPETENCIES / SKILLS

Technical:

- Cell line development: DNA to stable cell bank for protein biologics and gene therapy vectors
- Upstream development: process characterization, process transfer, small scale model, process/facility fit assessment, master batch record preparation/review/approval, risk assessment, deviation and CAPA review/classification/approval
- CMC development: early stage: pre-candidate to cell bank release; late stage: late-stage development, IND/BLA preparation, LIVCA & monoclonality definitions, submission and inspection support
- Technology transfer of cell line development and analytical methods
- Analytical assay method development and qualification
- Molecular cloning, Southern/Northern/Western blots, copy number (qPCR and ddPCR), Crispr-Cas9
- ClonePix, CloneSelect Imager, CellMetric, single cell printer, BLI Beacon, Ambr15
- Flow cytometry (analytical and sorting), operated BD Calibur, FACSAria, Celesta, LSR II, FACSArray & Sartorius iQue
- Microsoft Office suite (Word/Excel/PowerPoint/Visio/Teams/Project/OneNote/Sharepoint), Veeva Vault, JMP, FACSDiva, FlowJo, CellQuest, VectorNTI, SnapGene, Sequencher, GeneData Bioprocess, Freezerworks, FreezerPro, Miro, LucidChart, SmartSheets

Business:

- Operational excellence/Lean: defining project, workshop facilitation, process mapping/analysis, implementation, capacity modeling, Lean training for organization
- Experienced in global multicultural environments (US, Europe, and Asia)
- CDMO, CRO, and partner management
- Business processes support (procure to pay, capex, opex, logistics)

Organizational:

- People manager, direct reports and indirect reports in matrixed organization; performance management; people development; on-&off-boarding
- Presentation at group, department and project meetings; presentation at multiple management-level (departmental to executive) meetings on technical, CMC, and operations matters
- Diverse project management experience within and across functions, and with external partners at multiple engagement levels from leading teams to individual contributor
- Experienced with strategic thinking and tactical execution; Change management

PROFESSIONAL EXPERIENCE

4/2021 – Present	Moderna	Sr. Manager Technical Development Ops	Manager: Peter Wojciechowski
------------------	---------	------------------------------------------	---------------------------------

Responsibilities:

- As a member of Knowledge Management, conduct workshops and process mapping to facilitate understanding of knowledge/document flow from bench to regulatory submission, identify and affinitize gaps, and achieve consensus on improvement plan. Manage subteams to execute on improvement and implementation.
- Representing KM, support establishment of TechDev wide digital knowledge capture strategy including gathering VOC, establishing user requirements, and evaluation of external vendor capabilities.
- Additionally, supervised summer intern to establish an initial demonstration COGS model tool; supporting COGS process mapping to justify implementation of an optimized E2E COGS process and tool.

8/2020 – 3/2021	GSK	Sr. Manager Upstream Process Development	Manager: Mei Shao
-----------------	-----	---------------------------------------------	----------------------

- As a member of the Strategic External Development group, coordinate and manage externalized biologics programs at multiple CDMOs. Act as SME for cell line development, cell banking, LIVCA, and biosafety testing.
- As part of Upstream team, manage upstream development, at-scale bioreactor runs, PPQ readiness, and PPQ for Covid-19 neutralizing mAb project with Wuxi and VIR Biologics: coordinated WCB manufacturing/specification setting/testing/release, established GSK internal spec for MCB and WCB, LIVCA strategy and testing; supported MBR update and EBR review/approval; supported process characterization and associated technical report review/approval; supported Upstream lead in process transfer to Samsung Biologics such as small scale model studies to de-risk process and facility changes.
- Preparation of relevant modules for marketing application and IND amendment for the Covid-19 program.
- Supported legacy program for biosafety assay deviation, risk assessment, and PAI.

5/2003 – 7/2020	Sanofi (formerly Genzyme) Framingham, MA	Sr. Scientist Cell Line Development	Manager: Christine DeMaria
-----------------	---------------------------------------------	----------------------------------------	-------------------------------

- Supervision of up to three direct reports in preclinical CHO cell line development for biologics. Supervision and execution of AAV producer cell lines for gene therapy.
- Function representation on CMC or DS teams.
- Preparation and review of relevant technical reports and project related documents; preparation of cell substrate and LIVCA subsections for IND/BLA; respond/triage health authority questions.
- SME for cell line development, genetic characterization, monoclonality, and LIVCA on cross-functional teams.
- Science project team lead for research collaboration with outside partner to gain transcriptomic and metabolomic understanding of CHO expression platform, and to development optimized polishing conditions for platform purification method.
- Project core team member and workstream leader for operational excellence projects to improve CLD capacity/capability and to streamline global biologics material logistics process.
- Lean awareness training for CMC organization. Staff hiring, training, and development.

Key contributions:

- Serum-free CHO host cell line development: developed initial electroporation method, tested candidate host cell lines, and developed initial drug selection method, completed GS-knock out using Crispr-Cas9.
- Implemented codon optimization, and NGS for DNA and RNA sequence verification into cell line development work process.

JIN ZHANG

#262-22
274 AUBURNDALE AVE. NEWTON, MA 02466

- Supervised and/or performed cell line generation for >30 pre-clinical programs spanning wide range of modalities such as mono/bi/tri specific mAb, Fc-fusion, nanoparticle, nanobody, and enzyme; including several cell lines for life-cycle management of current commercial products.
- Since 2015, responsible for AAV cell line development for pre-clinical programs to ensure adherence to internal ways of working; completed 5 AAV cell line development with 1 IND approval to date.
- Genetic characterization assay redevelopment, qualification, and technical transfer for five current commercial products to meet more stringent health authority requirements.
- Supported 4 IND and 5 BLA submissions since 2019; of these 2 BLAs deemed corporate KPIs and approved/pending (US, Japan, EU); of these 1 IND approved.
- Trained FACSCalibur and FACSARIA operator; cell sorting support for department.

9/2000 – 3/2003	Ariad Pharmaceuticals Cambridge, MA	Research Associate Biology Group	Manager: Joëlle Gaschet
-----------------	----------------------------------------	-------------------------------------	-------------------------------

- Generation and characterization of retroviral (MMLV) production cell lines.
- Relevant molecular biology to generate expression vector and for genetic characterization.
- T-cell isolation from whole blood/buffy coat; T-cell stimulation/transduction.
- Flow cytometry and FACSCalibur operation.

2/1999 – 8/1999	Eisai Research Institute Andover, MA	Research Associate Contractor	Manager: Gabriel Berstein
-----------------	-----------------------------------------	----------------------------------	---------------------------------

- Expression vector construction and generation of a GPCR expressing cell line for compound screening.
- Assist in cell-based compound screening and Tecan robot implementation.

EDUCATION

9/1999 – 9/2000	Brandeis University Waltham, MA	Master's Molecular and Cell Biology	PI: Ruibao Ren
-----------------	------------------------------------	----------------------------------------	-------------------

- Animal handling, tail vein injection, bone marrow isolation, flow cytometry, tissue culture, necropsy.
- Conduct research to further define the animal model of CML and the roles of GM-CSF and IL-3, thesis titled: *Bcr-Abl Induces CML-like Myeloproliferative Disorder with Expansion of By-Stander Myeloid Cells Independent of IL-3 and GM-CSF in Mice*

8/1995 – 12/1998	Brandeis University Waltham, MA	Bachelor's of Science Biology	Bachelor's of Art Biochemistry
------------------	------------------------------------	----------------------------------	-----------------------------------

- Magna cum Laude.
- Undergraduate research on rad51 independent dsDNA break repair in *S.cerevisiae*, thesis titled: *Preference For Wild Type Double Strand Break Repair Pathway in a Sgs1, Rad51 Double Deletion Strain*

EMPLOYMENT AUTHORIZATION

NATURALIZED CITIZEN OF THE UNITED STATES OF AMERICA.

Carol Moore

From: Carol Moore
Sent: Wednesday, March 23, 2022 2:19 PM
To: City Council
Subject: New Docket Item - Finance

Councilors,

Council President Albright and Councilor Ryan have provided the Docket request below. Please let me know if you would like to sign on to the item for the Finance committee.

Resolution on the Fair Share Amendment.

Councilors Albright and Ryan, _____ requesting the following resolution asking the City Council to support the Fair Share Amendment which will be on the November Ballot.

(Please read draft resolution below)

WHEREAS, the best way to help working families and build a stronger economy for us all is to make sure that we have quality public schools for our children, affordable public higher education, and a reliable transportation system; and

WHEREAS, students need a well-rounded education, founded on a rich and varied curriculum that includes science, technology, engineering, and math (STEM), music, art, and athletics; and

WHEREAS, major investments in public education are needed to help students recover academically, socially, and emotionally from the COVID-19 pandemic; and

WHEREAS, tuitions and fees at our public colleges are among the highest in the country, and students are forced to take on enormous debt to receive a degree; and

WHEREAS, for Massachusetts to compete against other regions around the nation and the globe, we need modern, reliable transportation: safer roads and bridges, public transportation that works, and safe ways to walk and bike around town; and

WHEREAS, we have a large backlog of neglected and structurally compromised bridges, tunnels, roads, and public transportation infrastructure in need of repair; and

WHEREAS, new state revenue is necessary to rebuild crumbling roads and bridges, improve our public schools from Pre-K through college, invest in fast and reliable public transportation, make public higher education affordable again, and expand opportunities for healthy walking and bicycling; and

WHEREAS, Massachusetts needed new investments in our transportation and public education systems even before the COVID-19 pandemic, and now those investments are needed more than ever to lift our economy into an equitable and long-lasting recovery;

WHEREAS, our Commonwealth's highest-income residents, who have seen their collective net worth skyrocket in recent years, pay a lower percentage of their income in state and local taxes than do the rest of us, and clearly have the ability to pay a little more for the investments we all need;

THEREFORE, let it be resolved that the Newton City Council supports the proposed Fair Share Amendment that would create an additional tax of four percentage points on annual income above one million dollars and dedicate the funds raised by this tax to quality public education, affordable public colleges and universities, and for the repair and maintenance of roads, bridges, and public transportation.

--

**Susan Albright, President
Newton City Council
Councilor-at-Large Ward 2**